Impact of Spinal Mobilizations on Pain Modulation in People With Low Back Pain.

November 13, 2026 updated by: Mark Gugliotti, New York Institute of Technology

Preliminary Neurophysiological Effects of Grade II Versus Grade IV Lumbar Spinal Mobilization in Adults With Mechanical Low Back Pain: A Pilot fMRI Crossover Study.

Research shows 85% of the population will experience at least one episode of low back pain (LBP) in their lifetime. The annual cost to manage LBP in the U.S. can exceed 2 billion dollars. A conservative approach to LBP management can be provided by a physical therapist through interventions such as spinal mobilization. Spinal mobilizations are graded (I-IV) based upon the varying depths and impulse frequency at which they are applied to the target tissue. Functional magnetic resonance imaging (fMRI) studies have shown that spinal mobilizations (grade III, grade V) can stimulate pain suppression and provide favorable neurophysiological effects on pain modulation.

No studies to date, however, have examined the neurophysiological influence of grades II and IV on pain modulation. The purpose of this study is to investigate the change in pain suppression following spinal mobilization (i.e., grades II and IV).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

A conservative approach to LBP management can be provided by a physical therapist through interventions such as spinal mobilization. Spinal mobilizations are defined as passive movements to the spinal joints at varying speeds and amplitudes to restore accessory motion and optimize joint function. Spinal mobilizations are graded (I-IV) based upon the varying depths and impulse frequency in which they are applied to the target tissue. Grades I and II are applied more superficially to the tissue just prior to the onset of tissue resistance. These grades are often used for pain modulation in individuals who report high levels of pain and may present as reactive and irritable. Grades III and IV are applied deeper into the tissue resistance and are primarily used to increase tissue extensibility and joint mobility. These grades are often used with individuals who primarily report stiffness and mobility loss with lower levels of pain.

A proposed mechanism associated with spinal mobilization is the neurophysiological influence on pain modulation through activation of descending inhibitory pathways. Functional magnetic resonance imaging (fMRI) studies have shown that spinal mobilizations (grade III, grade V) can stimulate the salience network and provide favorable neurophysiological effects on pain modulation. This is determined by measuring the change in peak blood-oxygen-level-dependent (BOLD) signal from predefined regions of interest (ROIs). These ROIs include the prefrontal cortex, precuneus, anterior/posterior insulas, thalamus, anterior/posterior cingulate cortices, somatosensory cortex, secondary somatosensory cortex, and periaqueductal gray. Computing correlations between region pairs will determine functional connectivity (FC) and show which brain regions are most active.

No studies to date have examined the neurophysiological influence of grades II or IV on the salience network stimulation and pain modulation. These grades vary greatly with respect to their frequency and depth of application but may still provide similar pain modulation outcomes. The purpose of this study is to investigate the change in salience network stimulation following spinal mobilization (i.e., grades II and IV).

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

A. New York Tech students B. Age range: at least 18 years old C. Good overall health D. Mechanical low back pain ≥ 1 month *(source of pain is muscular or skeletal) E. Pain intensity of at least 4/10 or greater

Exclusion Criteria:

A. Claustrophobia B. IEDs including: pacemakers, internal defibrillators, and insulin pumps C. Medical implants or metallic foreign bodies, not limited ferrous metals D. Any previous history of lumbar surgery, nerve root involvement, stenosis (narrowing of the spinal canal), or mechanical instability E. Pregnancy F. Use of opioid medication G. LBP secondary to disease or systemic cause H. History of cardiovascular disease or high blood pressure I. History of Type I or Type II Diabetes J. History of neurodevelopmental disorders K. Prolonged steroid* use *(e.g., prednisone, dexamethasone, hydrocortisone, etc.) L. Oswestry Low Back Disability Index (ODI) score of <5 M. Inability to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Grade II lumbar spine mobilization

A grade II posterior-to-anterior spinal mobilization will be applied to the individual's lumbar spine for a total of five minutes.

A grade II spinal mobilization is applied to the spinal segment in a posterior-to-anterior direction to a tissue depth before the first onset of tissue resistance.

Experimental: Grade IV lumbar spinal mobiliation

A grade IV posterior-to-anterior spinal mobilization will be applied to the individual's lumbar spine for a total of five minutes.

Grade IV central posterior-to-anterior spinal mobilization will be applied to the lumbar spine for five minutes to a tissue depth of 50% of the tissue resistance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric Pain Rating Scale
Time Frame: At both sessions of care, from enrollment to the end of treatment at week 2

This 11-point numeric scale ranges from '0' representing one pain extreme (e.g., "no pain") to '10' representing the other pain extreme (e.g., "pain as bad as you can imagine" or "worst pain imaginable").

At both sessions of care, from enrollment to the end of treatment at week 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Mark Gugliotti, DPT, NYIT

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • NYIT IRB-2027-492

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.